Wednesday 4th November – Day 1 Main Conference - GMT (Greenwich Mean Time, GMTZ)
- Catherine Simpson - Conference Director - Cell and Gene Therapy Portfolio, Informa Connect LifeSciences
- Marion Hitchcock - Managing Director Gene & Cell Therapies Incubator Berlin and R&D Strategy & Portfolio Manager, Bayer
- Gunther Busam - Vice President, Global Manufacturing Technology and Supply, Orchard Therapeutics
- Bo Wiinberg - Chief Business Development Officer, Novo Nordisk Foundation Cellerator
- Artemy Shumskiy - Principal, LongeVC
- Christian Kannemeier - Senior Investment Manager, High-Tech Gründerfonds Management GmbH
- Ole Henrik Bang-Andreasen - Principal, Avant Bio
- Harry Starkey - Senior Conference Producer, Informa Connect
- Bernd Giebel - Founder & CTO, Exosla Therapeutics
- Madhusudhan Reddy Bobbili - Universitätsassistent (Assistant Professor), BOKU University
- Aadarash Zia - Senior Scientist - Drug Delivery, Medicines Discovery Catapult
- Rammohan Devulapally - Sr. Director, Head of Nonviral Delivery, Granza Bio
- Jenny van Asbeck-van der Wijst - CEO, Mercuna BV
- Charlotte Dunne - Senior Research Scientist, Pantherna Therapeutics GmbH
- Nicole Lund - Senior Director of Analytical & Quality Control, BlueRock Therapeutics
- Sarah Snykers - Head of Site Strategy & Excellence, Legend Biotech
- Anette Brass - Head of Process Development, Anocca AB
- Catherine Simpson - Conference Director - Cell and Gene Therapy Portfolio, Informa Connect LifeSciences
- Gunther Busam - Vice President, Global Manufacturing Technology and Supply, Orchard Therapeutics
- Christine Le Bec - Deputy CTO, Head of Analytical Development & QC, Sensorion
- Parag Kumthekar - Lead Gene Therapy Downstream Process Development, UCB
- Rutger Douma - MSAT Advanced Therapies Director, Johnson & Johnson Innovative Medicine
- Nazma Ilahibaks - CEO & Co-Founder, JAMA Therapeutics
- Robert Mamoun - CEO, Ciloa
- Lior Shaltiel - CEO, NurExone Biologic
- Heinrich Haas - Chief Technology Officer, NeoVac
- Rammohan Devulapally - Sr. Director, Head of Nonviral Delivery, Granza Bio
- Suzanne Saffie-Siebert - CEO, SiSaf Ltd
- Jenny van Asbeck-van der Wijst - CEO, Mercuna BV
- Heinrich Haas - Chief Technology Officer, NeoVac
Bringing advanced biotherapies to the clinic demands robust bioprocesses, rigorous quality control and full regulatory compliance. In this 10-minute talk, Clean Cells and Naobios, two companies of the Clean Biologics group based near Nantes, France, show how their complementary expertise supports developers from development to clinical batch. Clean Cells serves all types of biologics, including cell and gene therapies (CGT), and offers biosafety and quality control testing, GMP cell banks, BSL2/BSL3 virus seed stocks, secure storage and bespoke analytical tools. Its offering has recently expanded with the acquisitions of Stem Genomics, Anaquant and Xegen. Naobios, a CDMO, provides bioprocess development and GMP production of viral vaccines, oncolytic viruses and viral vectors, and also brings its expertise to extracellular vesicles. Together, we help clients accelerate their projects while maintaining the highest quality standards.
- François Pedelaborde, Business Development & Marketing Director, Clean Cells
- Gaëtan Blaize, Business Development & Marketing Director, Naobios
Two decades ago, NanoEntek introduced the world’s first automated cell counter. Today, the EVE HT FL and EVE HT A26 bring true high-throughput counting to cell and gene therapy, combining speed, accuracy and full walk-away automation for CGT process development, manufacturing and QC. Join our live demo to see the EVE HT A26 in action.
Join us at our 10-minute presentation at our booth to discover how NanoFCM’s single-particle analysis technology can provide deeper insights into the quality and heterogeneity of lipid nanoparticles (LNPs), lentiviral vectors (LVVs) and other nanoparticles. Find out how multiparameter characterization can reveal important features such as particle size, concentration, payload encapsulation, copy number and ligand marker expression per particle, and how it can identify distinct subpopulations that conventional bulk methods might miss. These insights can support the optimization of formulations, the development of processes and the assessment of quality, helping to advance the development of LNP-based therapeutics and viral vector applications.
- Volker Huppert - Chief Development Officer, Glycostem Therapeutics
- Nicole Lund - Senior Director of Analytical & Quality Control, BlueRock Therapeutics
- Ramiz Saramati - QA Operations Expert, Novartis
- Clotilde Ciesla - Upstream Development Engineer, Genethon
- Jordan Turnbull - Co-Founder, Co-CEO, CSO, Fuse Vectors
- Jelmer Willems - Senior Scientist, Group leader, Vector Development, VectorY
- Andreia Silva - Head of Research, Exogenus Therapeutics
- Rajeev Tawar - Associate Director, Vector and Analytical Development, Independant
- Alena Ivanova - Senior Scientist, AstraZeneca
- Shiran Shapira - CTO/CSO, Nano24
- Christian Reinsch - Vice President Technology Profiling, BioNTech SE
- Sébastien Wang - Responsable R&D, Silon Therapeutics
- Chuan-En Lu - Senior Scientist, AstraZeneca
- Aadarash Zia - Senior Scientist - Drug Delivery, Medicines Discovery Catapult
- Christin Zündorf - Chief Business Officer, TQ Therapeutics
- Parag Kumthekar - Lead Gene Therapy Downstream Process Development, UCB
- What is the single biggest milestone the exosome field must achieve by 2028 to maintain investor and pharma confidence?
- Native secretomes vs. engineered targeted vesicles: Which path crosses the clinical finish line first?
- Learning from the cell therapy playbook: How do we avoid the 20-year translational lag that plagued early MSCs?
- What will finally convince Big Pharma to commit to major licensing deals?
- Defining convincing clinical endpoints when exosome therapeutics operate across multiple biological mechanisms at once.
- Bernd Giebel - Founder & CTO, Exosla Therapeutics
- Alena Ivanova - Senior Scientist, AstraZeneca
- Madhusudhan Reddy Bobbili - Universitätsassistent (Assistant Professor), BOKU University
- Ka-Wai Wan - Expert Pharmaceutical / Quality Assessor, MHRA
